AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04425993 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sublingual Placebo
Description: All patients without contraindications should receive sublingual placebo within 5 minutes before ERCP.
Study NCT04425993 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sublingual Placebo
Description: All patients without contraindications should receive sublingual placebo within 5 minutes before ERCP.
Study NCT04425993 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rectal placebo
Description: All patients without contraindications should receive rectal placebo within 30 min before ERCP.
Study NCT04425993 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rectal placebo
Description: All patients without contraindications should receive rectal placebo within 30 min before ERCP.
Study NCT02881177 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: 40 IU
Study NCT02881177 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 40 IU
Study NCT01784913 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UV1 synthetic peptide vaccine and GM-CSF
Study NCT02325713 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral dispersible tablet of praziquantel (ODT-PZQ)
Description: Treatment A (test): ODT-PZQ (MSC1028703A) at a single dose of 40 milligram per kilogram (mg/kg) orally dispersed in water after meal.
Study NCT02325713 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cysticide
Description: Treatment B (reference): Cysticide tablet at a single dose of 40 mg/kg will be given with water orally after a meal.
Study NCT01097044 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afamelanotide
Description: One 16mg subcutaneous implant every 2 months for 6 months. (3 implants in total)
Study NCT01097044 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One placebo subcutaneous implant every 2 months for 6 months. (3 implants in total)
Study NCT02603133 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 1 Good Chat
Description: This tool uses the latest research on cultivating relationships and increasing social connection. Feeling socially connected is linked to health and well-being outcomes, including longevity.6 The 1 Good Chat tool asks participants to reflect on good conversations and to note the prosocial behaviors that he/she and the other person engaged in
Study NCT01148732 — intervention group
Intervention type: PROCEDURE
Intervention: ultrasonography
Description: a Toshiba 3.75 MHz convex ultrasonography transducer (Toshiba SSA-550A, Tochigi-ken, Japan) was placed transversely on the anterior neck just superior to the suprasternal notch and bilateral hemithorax by one of two emergency physician during emergency intubation investigators.
Study NCT03395964 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hybrid Dyna-CT guided localization
Description: We will perform intraoperative lung tumor localization in CGMH hybrid operation room(Room 51) equipped with the Siemens Artis Zeego system with DynaCT imaging capabilities. The system provides images equivalent to a 16-slice spiral CT scanner in a single 6-s sweep.
Study NCT00785577 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: LY545694 placebo BID po for 5 weeks~Pregabalin placebo capsules TID po for 6 weeks
Study NCT00785577 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin
Description: Pregabalin TID po for 6 weeks: 50 mg TID po for Week 1, 100 mg TID po for Weeks 2 - 5, and 50 mg TID po taper for Week 6~LY545694 placebo BID po for 5 weeks
Study NCT00785577 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY545694 21 mg
Description: LY545694 21 mg BID po for 1 week~Pregabalin placebo TID po for 6 weeks
Study NCT03395964 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Preoperative CT scan-guided localization
Description: Preoperative localization of the lung nodule will be carried out in the radiology department on the day of surgery using local anesthesia. CT-guided hook-wire or methyl blue dye will be placed percutaneously through a 22-gauge needle with the distal end deep to the nodule. The patient will then be taken to the operating room, where under general anesthesia with lung isolation, the nodule will be removed by wedge excision with endostaplers (Endo-GIA-II, United States Surgical,Norwalk, Conn; Echelon Endostapler, Ethicon Endo-Surgery, Cincinnati,Ohio) under the guidance of preoperative lung marking. If the lesion could not be excised using the VATS technique, the patient underwent an open thoracotomy.
Study NCT02949934 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tolcapone
Study NCT02325713 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ODT-PZQ
Description: Treatment C1 (test): ODT-PZQ (MSC1028703A) at a single dose of 20 mg/kg orally dispersed in water after a meal.
Study NCT02325713 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ODT-PZQ
Description: Treatment C2 (test): ODT-PZQ (MSC1028703A) at a single dose of 60 mg/kg orally dispersed in water after a meal.
Study NCT00785577 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY545694 49 mg
Description: LY545694 escalated to 49 mg BID po for 1 week during Week 2.~Pregabalin placebo TID po for 6 weeks.
Study NCT00785577 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY545694 105 mg
Description: LY545694 105 mg BID po for 5 weeks~Pregabalin placebo TID po for 6 weeks
Study NCT01212445 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG 3350 laxative plus electrolytes (PEG + E)/Macrogol (Movicol®, BAY81-8430)
Description: 13.125 g of PEG 3350 powder with approximately 0.6 g of electrolytes
Study NCT01167296 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cook balloon uterine stent
Description: Immediately before hysteroscopic surgery, a culture tip is inserted into the uterine cavity and sent for culture. Another culture was done 30 days later, and a second-look hysteroscope is done to evaluate the healing of uterine cavity.
Study NCT01167296 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cook balloon uterine stent
Description: Immediately before hysteroscopic surgery, a culture tip is inserted into the uterine cavity and sent for culture. Another culture was done 30 days later, and a second-look hysteroscope is done to evaluate the healing of uterine cavity.
Study NCT06656819 — intervention group
Intervention type: DEVICE
Intervention: Magstim Rapid2
Description: AIM 1: Investigate the estradiol effect on spinal circuit excitability post afferent (sensory) mediated subthreshold motor priming in young healthy women and men.~AIM 2: Characterize the Input output property of spinal circuit excitability following descending drive (motor) mediate priming in young healthy participants~AIM 3: Examine the estradiol effect on spinal circuit excitability following descending drive (motor) mediated priming in young healthy females
Study NCT03670576 — intervention group
Intervention type: PROCEDURE
Intervention: Optional Bronchoscopy
Description: Patients can decide to have an optional bronchoscopy so that samples can be taken for research up to three months from baseline.
Study NCT03670576 — intervention group
Intervention type: OTHER
Intervention: Quality of Life Questionnaires
Description: MRC Dyspnoea, SPARC, KBILD and EQ-5D-5L will be administered at baseline, 3 months, 12 months and 24 months,
Study NCT03670576 — intervention group
Intervention type: OTHER
Intervention: Blood Samples for Biomarkers
Description: a 40ml research blood sample to be taken at baseline, 3 months, 12 months and 24 months.
Study NCT03670576 — intervention group
Intervention type: OTHER
Intervention: Home Hand Held Spirometry
Description: Patients will download an app and are given a small hand held device to record their own spirometry at home. This is blinded for the first three months of the study and then requested a week before and a week after the three follow up points (3m, 12m, 24m)
Study NCT01607892 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KPT-330
Study NCT02971592 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MDcure
Description: reception of real working MDcure - device that does apply the electromagnetic field
Study NCT02971592 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Mock Device
Description: reception of device that does not apply the electromagnetic field
Study NCT02325713 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ODT-PZQ
Description: Treatment D1 (test): ODT-PZQ (MSC1028703A) at a single dose of 40 mg/kg orally dispersed in water without a meal.
Study NCT02325713 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cysticide
Description: Treatment D2 (reference): Cysticide crushed tablets at a single dose of 40 mg/kg will be given with water orally after a meal.
Study NCT02870946 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Simultaneous RRT
Description: The patients in the simultaneous RRT arm will receive RRT when ECMO is commenced. (see Study Description)
Study NCT02870946 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard care
Description: The patients in the standard care arm will not receive RRT when ECMO is commenced. Only when a patient demonstrates AKI and fulfills any one of the criteria of the conventional RRT indication, RRT would be delivered.
Study NCT04210193 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ALK Alutard 5-grasses
Description: 0.1 mL of 10 000 SQ-U/mL (1000 SQ-U) as an intralymphatic injection
Study NCT04210193 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ALK Diluent
Description: 0.1 mL of ALK Diluent as an intralymphatic injection
Study NCT02949934 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01767415 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indigo carmine
Description: During resection, a small quantity of a special dye called indigo carmine will be infused at the margins of the tumor using computer-guided stereotactic navigation equipment. This dye will be visible during the tumor resection and it can potentially serve as an additional marker of the tumor margins. A post-operative MRI scan -which is part of the standard care- will accurately measure the extent of tumor resection.
Study NCT05201417 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: adapted physical activity
Description: The adapted physical activity will be administered remotely through the whatsApp or YouTube application. Two sessions will be done per week: Wednesday and Sunday. Walking seems to be appropriate for all participants We will account for 24 APA sessions. We will leverage the Step Tracker phone app and pedometer to get the number of steps done, number of calories spent, Workout duration and distance walked per participant per APA session; this data will be collected weekly (after every two sessions)
Study NCT00533988 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Antimicrobial impregnated catheter (5593)
Description: Comparison of 14-day placement of a standard triple lumen (ARROW Standard Triple Lumen Catheter, Arrow International Inc., Reading, PA, US) versus an antimicrobial impregnated catheter (Chlorhexidine-silver sulfadiazine)(ARROWgard Triple Lumen Catheter, Arrow International Inc., Reading, PA, US)
Study NCT06736353 — intervention group
Intervention type: DRUG
Intervention: Beta Blocker Therapy or No Therapy (Control)
Description: Beta blocker therapy or no Beta blocker therapy initiated after type 2 myocardial infarction
Study NCT06736353 — intervention group
Intervention type: DRUG
Intervention: RAAS blocker Therapy or No therapy (Control)
Description: RAAS blocker therapy or no RAAS blocker therapy initiated after type 2 myocardial infarction
Study NCT06736353 — intervention group
Intervention type: DRUG
Intervention: Statin Therapy or No Therapy (Control)
Description: Statin therapy or no Statin therapy initiated after type 2 myocardial infarction
Study NCT06736353 — intervention group
Intervention type: DRUG
Intervention: Single Antiplatelet Therapy or No Therapy (Control)
Description: Single Antiplatelet Therapy or no Single Antiplatelet Therapy therapy initiated after type 2 myocardial infarction
Study NCT06736353 — intervention group
Intervention type: DRUG
Intervention: Dual Antiplatelet Therapy or No Therapy (Control)
Description: Dual Antiplatelet Therapy or no Dual Antiplatelet Therapy initiated after type 2 myocardial infarction
Study NCT03863743 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: integrated care pathway
Description: Incidence of POUR after undergoing total hip or knee replacement and integrated care pathway will be evaluated.
Study NCT03863743 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: physician's standard of care
Description: Incidence of POUR will be evaluated in standard of care treatment.
Study NCT01813032 — intervention group
Intervention type: PROCEDURE
Intervention: Forearm Vascular Study
Description: Forearm venous occlusion plethysmography to measure forearm blood flow during intra-arterial infusion of the vasodilators Verapamil (10-100 µg/min), bradykinin (100-1000 pmol/min), sodium nitroprusside (2-8 µg/min) and Acetylcholine (5-20 µg/min).
Study NCT01813032 — intervention group
Intervention type: PROCEDURE
Intervention: Badimon Chamber
Description: Ex-vivo assessment of thrombus formation using the Badimon Chamber
Study NCT02585037 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesio Taping® bandage
Description: The Kinesio Taping® bandage will be applied in an I format in the wrist flexor muscles of a dominant and non-dominant limb in G1 and G2 groups.
Study NCT02585037 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Dynamometer Jamar® pressure
Description: The Jamar® dynamometer will be adjusted to the second position for measurement of maximal voluntary strength of handgrip. A muscle contraction period of three seconds will be performed in order to record handgrip strength.
Study NCT01116050 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol
Description: 5 tablets of 200 microgram geach intra rectal by opaque introducer
Study NCT01116050 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 5 tablets in opque introducer
Study NCT02029976 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SNAPSHOT (Student, Nurses and Parents Seeking Healthy Options Together)
Description: attention control condition after school weight management program
Study NCT02029976 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mailed monthly newsletters
Description: Newsletters
Study NCT03027167 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Study NCT03027167 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Study NCT03027167 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: (Post- discharge) Mechanical Compression Device
Study NCT02149641 — intervention group
Intervention type: RADIATION
Intervention: Intensity modulated radiotherapy with chemotherapy
Study NCT03109431 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Level 1
Description: Youth will receive 1-5 text messages per day for at least 12 months. Banks of about 750 messages (70-120 messages per domain) focus on the HIV Treatment Continuum, with messages focused on dedicated to healthcare, wellness, sexual health, drug use and medication reminders. Youth will be able to choose the time and frequency that they receive daily texts. Preferences for the timing and type of messages can be updated at 4-month assessment points.~Youth will complete weekly monitoring surveys by text message. The survey will cover six domains related to the HIV Treatment Continuum. If YLH do not respond to the text, reminder messages will be sent to the youth. After three days of non-response a follow-up call by an interviewer will be made to the YLH.
Study NCT03109431 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Level 2
Description: Youth will be enrolled in online, private discussion groups.~Peer Support will be offered by fellow participants and/or Youth Advisory Board members that have been trained in basic information on HIV, STI, drug use, mental health, homelessness, and stigma; using social media to create wall posts and use chat functions; and, how to initiate conversations on sensitive topics. By posting and responding to messages, Peer Supporters will encourage and broadly guide conversation related to the HIV Prevention Continuum, and other relevant topics.~Coaches and Project Coordinators will be available to provide factual information (as needed), and remove inappropriate content.
Study NCT03109431 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Level 3
Description: Youth will have be assigned to a Coach trained in a strengths--based Coaching intervention, as well as common foundational theory, principles and skills used in adolescent HIV Evidence-Based Interventions (EBI). Youth preferences will drive the intervention delivery - whether in-person, electronically via the phone, email, text message, social media private messaging.
Study NCT02031679 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1981
Description: AZD1981 is an oral, potent, selective, reversible antagonist of CRTh2 (Chemoattractant Receptor Homologous Molecule expressed on Th2 cells).
Study NCT02031679 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sugar pill manufactured to mimic AZD1981 10 mg tablet
Study NCT02585037 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dynamometer Jamar® pressure
Description: The Jamar® dynamometer will be adjusted to the second position for measurement of maximal voluntary strength of handgrip. A muscle contraction period of three seconds will be performed in order to record handgrip strength.
Study NCT02585037 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: For the control group (G3) the Kinesio Taping® bandage will be placed from the lateral extremity to the medial axis.
Study NCT03376841 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cenicriviroc
Description: 1 tablet; single-dose oral administration
Study NCT02127905 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: CD34+ selected cells
Description: Compassionate treatment of Fanconi Anemia patients with unrelated bone marrow or peripheral blood HSCT followed by the infusion of CD34+ selected cells using CliniMACS
Study NCT05438615 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Corneal Refractive Therapy-spherical
Description: A comparison of two different designs of Corneal Refractive Therapy contact lenses will be done. Each will be worn for two weeks. The sponsor will mask which lens will be first or second in the trial.
Study NCT05438615 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Corneal Refractive Therapy-aspherical
Description: A comparison of two different designs of Corneal Refractive Therapy contact lenses will be done. Each will be worn for two weeks. The sponsor will mask which lens will be first or second in the trial.
Study NCT03197285 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Combined Physiotherapy Protocol
Description: Thermotherapy (70 w continuous microwave for 10 minutes), therapeutic massage (surface rubbing for 5 minutes, 10 minutes of compression and kneading massage and 2 minutes of final surface friction), application of analgesic currents (TENS, by self-adhesive silicone electrodes 4x4 cm, symmetrical biphasic rectangular current, 200 µs width pulse, a frequency of 1 Hz for 10 minutes. The patient should notice a slight vibration, without it being painful).
Study NCT00061620 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tezacitabine (FMdC)
Description: 7.5 mg/m2 bolus infusion daily x 5
Study NCT00556348 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: 1.25mg
Study NCT03820531 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Next Generation Sequencing
Description: DNA Mutational Analysis in pancreas cyst fluid concerning KRAS/GNAS-mutations and mutations in tumor supressor genes
Study NCT03820531 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: CEA and lipase
Description: Measuring CEA and lipase level in pancreas cyst fluid:~CEA > 192 ng/ml and lipase > 200 U/l = mucinous cyst
Study NCT03820531 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Cytology
Description: Cytology in pancreas cyst fluid:~mucinous versus non-mucinous cyst; LGD versus HGD/Carcinoma
Study NCT03820531 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Histology of resected pancreas cyst
Description: Histology of resected pancreas cyst concerning mucinous versus non-mucinous cyst, IPMN versus non-IPMN and LGD versus HGD/Carcinoma
Study NCT01463917 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hypertonic solution
Description: Use of Hypertonic solution 4 ml/Kg during left marginal branch CABG surgery.
Study NCT03135392 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Breast Reconstruction with Artificial Implant
Description: Patients undergo unilateral or bilateral reconstruction of breasts after nipple sparing mastectomy. Breasts are reconstructed with artificial implants
Study NCT03135392 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Breast Reconstruction
Description: Patients undergo unilateral or bilateral reconstruction of breasts after nipple sparing mastectomy. Breasts are reconstructed with the patient's own tissue
Study NCT02737046 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belinostat
Description: Belinostat will be administered as 1,000 mg/m2 IV infusion over 30 minutes on Days 1- 5 every 21 days (Exception as per FDA-approved Package Insert: In patients known to be homozygous for the UGT1A1\*28 allele, the starting belinostat dose must be 750mg/m2) for up to 8 cycles.